Literature DB >> 7599036

Comparison of basic fibroblast growth factor levels in clone A human colon cancer cells in vitro with levels in xenografted tumours.

L P McCarty1, S M Karr, B Z Harris, S G Michelson, J T Leith.   

Abstract

We measured levels of basic fibroblast growth factor (FGF-2) in human colon cancer cells (clone A) in vitro and in xenografted solid tumours using a commercial enzyme-linked immunoassay. In Vitro, levels in unfed plateau phase or exponentially growing cells were low, averaging respectively about 2 and 8 pg 10(-6) cells. However, when solid tumours (average volumes 787 mm3) were cut into halves and either enzymatically disaggregated to obtain a cellular fraction or extracted in toto, levels were much higher. In the cellular fraction, values averaged 110 pg 10(-6) cells, while in whole tumour extracts, average values were 24 pg mg-1 tumour tissue. These results indicate that growth factor levels in solid neoplasms may differ markedly from those predicted from in vitro measurements. We hypothesise that the apparent increase in FGF-2 levels in vivo results primarily from the presence of a significant fraction of host cells (in particular, macrophages, which may contain high levels of FGF-2) within xenografted clone A neoplasms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7599036      PMCID: PMC2034148          DOI: 10.1038/bjc.1995.269

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  Angiogenesis research spreads to clinic.

Authors:  S Jenks
Journal:  J Natl Cancer Inst       Date:  1994-05-18       Impact factor: 13.506

2.  Clinical and pharmacological implications of cancer cell differentiation and heterogeneity.

Authors:  P Calabresi; D L Dexter; G H Heppner
Journal:  Biochem Pharmacol       Date:  1979-06-15       Impact factor: 5.858

3.  Cell cycle distribution of chronically hypoxic cells and determination of the clonogenic potential of cells accumulated in G2 + M phases after irradiation of a solid tumor in vivo.

Authors:  M G Pallavicini; M E Lalande; R G Miller; R P Hill
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

4.  Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers.

Authors:  M Nguyen; H Watanabe; A E Budson; J P Richie; D F Hayes; J Folkman
Journal:  J Natl Cancer Inst       Date:  1994-03-02       Impact factor: 13.506

5.  Expression of basic and acidic fibroblast growth factors and their receptor in normal and atherosclerotic human arteries.

Authors:  S E Hughes; D Crossman; P A Hall
Journal:  Cardiovasc Res       Date:  1993-07       Impact factor: 10.787

6.  Cell loss from viable and necrotic tumour regions measured by 125I-UdR.

Authors:  R Porschen; W Porschen; H Mühlensiepen; L E Feinendegen
Journal:  Cell Tissue Kinet       Date:  1983-11

7.  Heterogeneity of cancer cells from a single human colon carcinoma.

Authors:  D L Dexter; E N Spremulli; Z Fligiel; J A Barbosa; R Vogel; A VanVoorhees; P Calabresi
Journal:  Am J Med       Date:  1981-12       Impact factor: 4.965

8.  Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels.

Authors:  F Goto; K Goto; K Weindel; J Folkman
Journal:  Lab Invest       Date:  1993-11       Impact factor: 5.662

9.  Effect of X-irradiation on host-cell infiltration and growth of a murine fibrosarcoma.

Authors:  R Evans
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

10.  Cell subpopulations dispersed from solid tumours and separated by centrifugal elutriation.

Authors:  D W Siemann; E M Lord; P C Keng; K T Wheeler
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

View more
  1 in total

1.  Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.

Authors:  L Y Dirix; P B Vermeulen; A Pawinski; A Prové; I Benoy; C De Pooter; M Martin; A T Van Oosterom
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.